Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of potential biomarkers and therapeutic targets related to post-traumatic stress disorder due to traumatic brain injury. | Eur J Med Res | 2024 | 38212778 | PubTator, text mining | PubMed |
| The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma. | Heliyon | 2024 | 38205335 | PubTator, text mining | PubMed |
| N-linked Fc glycosylation is not required for IgG-B-cell receptor function in a GC-derived B-cell line. | Nat Commun | 2024 | 38195612 | PubTator, text mining | PubMed |
| CD47 overexpression is related to tumour-associated macrophage infiltration and diffuse large B-cell lymphoma progression. | Clin Transl Med | 2024 | 38193627 | PubTator, text mining | PubMed |
| Single-cell transcriptomic analyses of tumor microenvironment and molecular reprograming landscape of metastatic laryngeal squamous cell carcinoma. | Commun Biol | 2024 | 38191598 | PubTator, text mining | PubMed |
| Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. | Cancer Med | 2024 | 38180169 | PubTator, text mining | PubMed |
| Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma. | Exp Hematol Oncol | 2024 | 38173015 | PubTator, text mining | PubMed |
| Diagnostic methods for primary vitreoretinal lymphoma: A systematic review. | Surv Ophthalmol | 2024 | 38163550 | PubTator, text mining | PubMed |
| FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect. | Heliyon | 2024 | 38163206 | PubTator, text mining | PubMed |
| EFNB1 levels determine distinct drug response patterns guiding precision therapy for B-cell neoplasms. | iScience | 2024 | 38155773 | PubTator, text mining | PubMed |
| Current Status of Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasms in Korea. | Ann Lab Med | 2024 | 38145891 | PubTator, text mining | PubMed |
| Altered Transcriptome Response in PBMCs of Czech Adults Linked to Multiple PFAS Exposure: B Cell Development as a Target of PFAS Immunotoxicity. | Environ Sci Technol | 2024 | 38112183 | PubTator, text mining | PubMed |
| Genomic insights and prognostic significance of novel biomarkers in pancreatic ductal adenocarcinoma: A comprehensive analysis. | Biochem Biophys Rep | 2024 | 38107664 | PubTator, text mining | PubMed |
| Farm forests, seasonal hunger, and biomass poverty: Evidence of induced intensification from panel data in the Ethiopian Highlands. | Ambio | 2024 | 38100004 | PubTator, text mining | PubMed |
| Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas. | Cancer Immunol Res | 2024 | 38091354 | PubTator, text mining | PubMed |
| gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve. | CPT Pharmacometrics Syst Pharmacol | 2024 | 38082557 | PubTator, text mining | PubMed |
| Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. | Nat Med | 2024 | 38072960 | PubTator, text mining | PubMed |
| Phosphatidylserine synthesis controls oncogenic B cell receptor signaling in B cell lymphoma. | J Cell Biol | 2024 | 38048228 | PubTator, text mining | PubMed |
| Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: A comprehensive review of the current literature. | Clin Transl Sci | 2024 | 37905360 | PubTator, text mining | PubMed |
| Men treated with BEACOPP for Hodgkin lymphoma may be at increased risk of testosterone deficiency. | Ann Hematol | 2024 | 37870576 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=16